EXTREMELY IMPORTANT MAIL!! Possible life-saving E-mail……please read and forward
Some investigators have suggested that administration of minocycline may be suitable as a general treatment of patients with acute stroke that is safe and can be used in both ischemic and hemorrhagic strokes as a single treatment.
Since some 12-13 years already I advise any patient with an increased risk for a TIA/CVA [hypertension, diabetes etc]to keep minocycline at home and to use it if necessary.[this as a result of an article from Yairs Lampl, M.D., Edith Wolfson Medical Center and Tel Aviv University in Israel.]
For totally not understandable reasons hospitals and neurologists still, don’t know or don’t want to know about the use of minocycline for the treatment and even prevention of TIA/CVA.
Whenever I suggested this [when a patient was hospitalized] doctors refused even to listen.
I am sending you a new article below as well as an attachment with what I wrote about in the past.
Minocycline: A Novel Stroke Therapy
Journal of Neurology and Stroke
, Aage R. Møller60
(University of Texas at Dallas)The only FDA approved treatment for ischemic strokes is tissue plasminogen activator (tPA). The benefit of treatment with tPA is limited and it has to be administrated within a short time window; furthermore, the side effects are serious including increased risk of subsequent hemorrhagic transformation. This review discusses minocycline’s role in neuroprotection, and it discusses the results of five published clinical trials regarding the use of administration of minocycline for treatment of acute stroke. The studies find that the benefit of tPA treatment alone is limited and has serious side effects. While many new agents have been studied to ameliorate this, minocycline, a tetracycline antibiotic, seems the most promising.
Some investigators have suggested that administration of minocycline may be suitable as a general treatment of patients with acute stroke that is safe and can be used in both ischemic and hemorrhagic strokes as a single treatment that may provide benefits in reducing the deficits from ischemic strokes with little side effects.